The aim of the study was to compare on both tumoral and stromal cells the expression of genes related to androgen and estrogen Sepantronium datasheet metabolism in paired samples of prostate cancers collected before androgen deprivation

therapy (ADT) and after hormonal relapse. The study included 55 patients treated only by ADT for prostate cancer, and for whom tissues were available before treatment induction and after recurrence. Gene expressions were analysed using immunohistochemistry performed on tissue microarray, using antibodies directed against: androgen receptor (AR), phosphorylated AR (pAR), estrogen receptor alpha (ERA), estrogen receptor beta (ERB), 5 alpha reductase 1 and 2, aromatase,

BCAR1 (involved in antiestrogen resistance in breast cancer), and the proliferation marker Ki67. Expressions were compared using Friedman selleck and Wilcoxon paired tests. Predictive expressions of overall survival and the time to hormonal relapse were analysed using Log-rank and Cox tests. When compared to hormone sensitive samples, tissues collected after hormonal relapse were characterized by increased expression of Ki67, AR, pAR (p < 0.001), and BCAR (p = 0.03), and by lower staining for 5AR2 (p = 0.002), ERB (p = 0.016), and aromatase (p < 0.001). Shorter time to hormonal relapse was associated with high expressions of aromatase and BCAR on diagnostic biopsies, together with low stromal staining for ERA. Overall survival was significantly shorter when tissues collected after relapse displayed both high proliferation index and low ERA expression in stromal cells. These results demonstrated a dysregulation of proteins involved not only in androgen pathways but also in estrogen synthesis and signalling during the development of HRPC. The survival advantage of ERA staining in HRPC

underlines the importance of steroid signalling via the microenvironment in prostate cancer. Poster No. 184 Is there a Relationship between the Expression of CD147 (EMMPRIN), Edoxaban CD44, Multidrug Resistance (MDR) and Monocarboxylate (MCT) Transporters, and Prostate learn more cancer (CaP) Progression? Jingli Hao 1,2 , Michele C. Madigan3, Hongmin Chen 2, Paul J. Cozzi1,4, Warick J. Delprado5, Yong Li1,2 1 Faculty of Medicine, University of New South Wales, Kensington, New South Wales, Australia, 2 Cancer Care Centre, St George Hospital, Kogarah, New South Wales, Australia, 3 School of Optometry & Vision Science, University of New South Wales, Kensington, New South Wales, Australia, 4 Department of Surgery, St George Hospital, Kogarah, New South Wales, Australia, 5 Pathology, Douglass Hanly Moir, North Ryde, New South Wales, Australia Aim: Multidrug resistance (MDR) and metastasis are the main causes of treatment failure in prostate cancer (CaP) patients.